Each member of the popular and closely-watched FAANG stocks, as well as Microsoft, reported their most recent quarterly earnings in October – and the gains that followed some solid earnings figures helped propel the S&P 500 to an all-time high. For how each of the FAANG stocks (and Microsoft) performed in quarterly earnings, as well as how much each stock has gained so far this year, CLICK HERE.
“Tech stocks can be fickle and volatile — but they can also experience rapid growth in short periods of time,” notes the author of today’s article, who identifies five “up and coming” companies in the technology sector that traders may want to consider keeping an eye on. For these five tech stocks to watch – including a designer and manufacturer of MRI equipment and a company whose stock has seen phenomenal growth (and numerous Buy ratings from analysts) – CLICK HERE.
The past few weeks have seen an unusual activity in the tech sector: significant insider buying at more than a dozen tech firms, especially chip companies. As the author of today’s article notes, studies “have consistently shown that buying by corporate insiders often precedes bullish moves in stocks, sectors, and the market overall.” So, despite current worries about the market and the economy, there may be reason to be bullish on tech – and the author highlights a number of tech names that have seen recent insider buying. For more, CLICK HERE.
After a particularly rough fourth quarter in 2018, tech stocks have been staging an impressive recovery so far this year – but Morgan Stanley is warning that, due to bleak growth prospects, lofty valuations and various other potential challenges, tech stocks could be particularly vulnerable when the current market rally starts to peter out later this year. Still, the firm does see some opportunities in the sector. For more, CLICK HERE.
Tech stocks have been on a tear – and the three tech stocks highlighted in today’s article have been out front. Yet while each of these stocks has gained at least 35% (and up to 67%) this year, they are still trading below fair value estimates. Moreover, the author notes, “these stocks all boast wide economic moats and stable or positive moat trends; these aren’t flashes in the pan, but rather powerful competitors positioned to endure.” For these three tech stocks that have seen impressive run-ups this year – and still have more room to run – CLICK HERE.
With September historically being a weak month for tech stocks (and the market in general), how might one go about trading the FAANG stocks this month and into October? Today’s article examines the price cycles of Facebook, Amazon, Apple, Netflix and Google – and what they indicate about how to trade these stocks in the coming weeks. What do the charts have to say about what to buy, what to sell – and when? CLICK HERE.
In compiling its “Imagine 2025” portfolio, analysts at RBC Capital Markets sought to identify companies “they felt were positioning most boldly and effectively for the future.” The result is a list of 75 stocks “set to dominate the next decade of innovation and growth” – and today’s article highlights the tech stocks that made the list. For the tech stocks that RBC believes are positioned to “own the future” – and why – CLICK HERE.
As tech stocks have been on a tear, technology exchange-traded funds have been the recipients of increased attention – and money inflows. While the typical investor may elect to go with a broad-based tech ETF, there are some alternative picks that may be of interest to more discerning tech investors – and today’s article highlights three of them: a fund that seeks out firms with the most promising technologies globally, a fund that concentrates on the high-growth cloud computing space, and a fund that takes a middle-ground approach to the large-cap vs. small-cap tech stock debate. For more, CLICK HERE.
Hot tech stocks may have gotten the bulk of the attention in 2017, but today’s article observes that the best stock market trade last year didn’t even involve a specific stock. That trade? Shorting volatility, with the author noting that “two exchange-traded products betting against US stock volatility skyrocketed almost 200% in 2017 through Christmas, dwarfing returns for the absolute hottest mega-cap tech stocks.” But with a growing number of voices sounding the alarm over this strategy, is now the time to get in on the other side of the trade? CLICK HERE for more.
With only 10% of drug candidates that reach the clinical trial stage eventually making their way onto the market, knowing which small biotechs to bet on for big gains is no easy feat for investors. The author of today’s article suggests that one way investors can increase their odds of success is by identifying small biotechs that are getting the attention (and money) of big pharma companies. He proceeds to highlight one such company, which “has developed an innovative product that makes other drugs more effective” – attracting capital from the likes of Roche, Johnson & Johnson and more. To read about this company, the science behind its technology – and the opportunity for investors – CLICK HERE.